Hep C patients claim Bristol-Myers rushed into trial

Did Bristol-Myers Squibb ($BMY) rush an experimental hepatitis C drug trial, despite signs that the treatment could be toxic? Some patients who suffered injury during the study say so--and they're suing the drugmaker for damages. Report